EyePoint Pharmaceuticals, Inc.
EYPT
$5.68
$0.1252.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -41.00% | 4.75% | -5.27% | -107.70% | -11.79% |
| Total Depreciation and Amortization | 14.46% | 12.71% | 19.47% | 170.54% | -2.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.95% | -20.46% | -42.24% | 284.77% | -12.23% |
| Change in Net Operating Assets | 92.99% | -576.55% | 122.94% | -16.63% | -94.90% |
| Cash from Operations | 8.15% | -93.42% | 35.27% | -34.89% | -51.99% |
| Capital Expenditure | 75.60% | -74.89% | 24.62% | -35.22% | 48.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -637.86% | 111.14% | -824.98% | 147.55% | -- |
| Cash from Investing | -692.50% | 110.10% | -870.91% | 144.13% | -2,641.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 56.16% | -- | -- | -- | -- |
| Issuance of Common Stock | 1,162.72% | 1,827.04% | -86.29% | -97.91% | 1,927.66% |
| Repurchase of Common Stock | 100.00% | 0.00% | 98.21% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -144.94% | -147.22% | 91.33% |
| Cash from Financing | 1,175.41% | 3,514.89% | 186.09% | -99.95% | 2,008.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 281.68% | 93.93% | -1,658.48% | -106.92% | 2,358.88% |